Stock AnalizGilead Sciences (GILD) earnings for the quarter ended September 2026: EPS beats estimates
Gilead Sciences reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at $2.55 against the analysts’ average forecast of $2.19, a beat of 16.2%.
Revenue for the quarter was $8.30 billion, up 6.8% from $7.77 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 7.2% on the first trading day after the report.
The last four quarters
Gilead Sciences has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $2.55 | $2.19 | +16.2% | +7% | +7.2% |
| Jun 2026 | -$6.75 | -$7.25 | +6.9% | +10% | +0.5% |
| Mar 2026 | $2.03 | $1.91 | +6.2% | +4% | −3.6% |
| Sep 2025 | $2.47 | $2.14 | +15.7% | +3% | +1.1% |
What comes next
Analysts expect EPS of $1.09 for the next quarter on average and -$0.98 for the fiscal year ending December 31, 2026.
The average analyst price target is $174.77, 4% above the current price of $168.08.
Valuation and score
Gilead Sciences scores 2.8 out of 5 overall on Stock Analiz (average), and its intrinsic value under moderate assumptions is about 35% below the current market value. Full Gilead Sciences analysis with 10 years of financials
Frequently asked questions
What was Gilead Sciences’s EPS for the quarter ended September 2026?
$2.55 adjusted per share, against an analyst consensus of $2.19.
How much revenue did Gilead Sciences report?
$8.30 billion, up 6.8% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.